Sunovion Pharmaceuticals Inc. Submits Supplemental New Drug Application Seeking Approval for the Use of Aptiom as Monotherapy Treatment for Partial-Onset Seizures )--Sunovion Pharmaceuticals Inc. today announced that it has submitted a supplemental new drug application to the U.S. Food and Drug Administrati... )--FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code --MMRF Launches Dr. Elsey's Fund to Cure Cancer.